(CPRX) Catalyst Pharmaceuticals - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.801m | Total Return -5.8% in 12m
Stock: Rare Disease Treatments, Seizure Medication, Muscle Disorder Drug
Total Rating 59
Risk 76
Buy Signal -0.26
| Risk 5d forecast | |
|---|---|
| Volatility | 40.3% |
| Relative Tail Risk | -7.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -17.75 |
| Character TTM | |
|---|---|
| Beta | 0.765 |
| Beta Downside | 1.012 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.39% |
| CAGR/Max DD | 0.34 |
EPS (Earnings per Share)
Revenue
Description: CPRX Catalyst Pharmaceuticals March 04, 2026
Catalyst Pharmaceuticals, Inc. (CPRX) is a commercial-stage biopharmaceutical company specializing in treatments for rare diseases in the United States. The companys portfolio includes Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS), Fycompa for seizure disorders, and AGAMREE for Duchenne Muscular Dystrophy. The biopharmaceutical sector often focuses on high-cost, low-volume therapies for specialized patient populations.
CPRX operates through a business model that includes both proprietary drug development and strategic licensing agreements, such as those with BioMarin Pharmaceutical Inc. and Endo Ventures Limited. This hybrid approach allows for both internal innovation and expanded market reach through partnerships. Further research on platforms like ValueRay can provide deeper insights into the companys financial performance and market position.
Headlines to watch out for
- Firdapse sales growth drives revenue
- Fycompa sales expand epilepsy market share
- AGAMREE launch impacts rare disease revenue
- Generic Sabril competition affects market
- Regulatory approvals for new indications boost stock
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 214.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA -9.25 > 1.0 |
| NWC/Revenue: 126.8% < 20% (prev 102.3%; Δ 24.53% < -1%) |
| CFO/TA 0.19 > 3% & CFO 208.7m > Net Income 214.3m |
| Net Debt (-706.4m) to EBITDA (313.1m): -2.26 < 3 |
| Current Ratio: 6.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (127.3m) vs 12m ago 0.77% < -2% |
| Gross Margin: 85.19% > 18% (prev 0.86%; Δ 8.43k% > 0.5%) |
| Asset Turnover: 60.16% > 50% (prev 57.76%; Δ 2.40% > 0%) |
| Interest Coverage Ratio: -34.80 > 6 (EBITDA TTM 313.1m / Interest Expense TTM -7.92m) |
Altman Z'' 10.00
| A: 0.67 (Total Current Assets 894.0m - Total Current Liabilities 147.2m) / Total Assets 1.11b |
| B: 0.43 (Retained Earnings 474.2m / Total Assets 1.11b) |
| C: 0.28 (EBIT TTM 275.6m / Avg Total Assets 979.1m) |
| D: 3.11 (Book Value of Equity 474.3m / Total Liabilities 152.5m) |
| Altman-Z'' Score: 10.98 = AAA |
Beneish M -2.51
| DSRI: 1.64 (Receivables 128.3m/65.5m, Revenue 589.0m/491.7m) |
| GMI: 1.01 (GM 85.19% / 86.00%) |
| AQI: 0.72 (AQ_t 0.19 / AQ_t-1 0.26) |
| SGI: 1.20 (Revenue 589.0m / 491.7m) |
| TATA: 0.01 (NI 214.3m - CFO 208.7m) / TA 1.11b) |
| Beneish M-Score: -2.51 (Cap -4..+1) = A |
What is the price of CPRX shares?
As of March 29, 2026, the stock is trading at USD 23.40 with a total of 754,794 shares traded.
Over the past week, the price has changed by +2.68%, over one month by +1.39%, over three months by -2.74% and over the past year by -5.80%.
Over the past week, the price has changed by +2.68%, over one month by +1.39%, over three months by -2.74% and over the past year by -5.80%.
Is CPRX a buy, sell or hold?
Catalyst Pharmaceuticals has received a consensus analysts rating of 4.86.
Therefore, it is recommended to buy CPRX.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34 | 45.3% |
| Analysts Target Price | 34 | 45.3% |
CPRX Fundamental Data Overview March 29, 2026
P/E Trailing = 13.5655
P/E Forward = 9.3809
P/S = 4.7559
P/B = 2.9166
Revenue TTM = 589.0m USD
EBIT TTM = 275.6m USD
EBITDA TTM = 313.1m USD
Long Term Debt = 2.79m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 437k USD (from shortTermDebt, last quarter)
Debt = 2.79m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -706.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.09b USD (2.80b + Debt 2.79m - CCE 709.2m)
Interest Coverage Ratio = -34.80 (Ebit TTM 275.6m / Interest Expense TTM -7.92m)
EV/FCF = 10.04x (Enterprise Value 2.09b / FCF TTM 208.6m)
FCF Yield = 9.96% (FCF TTM 208.6m / Enterprise Value 2.09b)
FCF Margin = 35.42% (FCF TTM 208.6m / Revenue TTM 589.0m)
Net Margin = 36.39% (Net Income TTM 214.3m / Revenue TTM 589.0m)
Gross Margin = 85.19% ((Revenue TTM 589.0m - Cost of Revenue TTM 87.3m) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 82.94%)
Tobins Q-Ratio = 1.89 (Enterprise Value 2.09b / Total Assets 1.11b)
Interest Expense / Debt = 61.14% (Interest Expense 1.70m / Debt 2.79m)
Taxrate = 26.71% (19.2m / 71.9m)
NOPAT = 202.0m (EBIT 275.6m * (1 - 26.71%))
Current Ratio = 6.08 (Total Current Assets 894.0m / Total Current Liabilities 147.2m)
Debt / Equity = 0.00 (Debt 2.79m / totalStockholderEquity, last quarter 954.3m)
Debt / EBITDA = -2.26 (Net Debt -706.4m / EBITDA 313.1m)
Debt / FCF = -3.39 (Net Debt -706.4m / FCF TTM 208.6m)
Total Stockholder Equity = 881.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.89% (Net Income 214.3m / Total Assets 1.11b)
RoE = 24.32% (Net Income TTM 214.3m / Total Stockholder Equity 881.2m)
RoCE = 31.18% (EBIT 275.6m / Capital Employed (Equity 881.2m + L.T.Debt 2.79m))
RoIC = 22.92% (NOPAT 202.0m / Invested Capital 881.2m)
WACC = 8.66% (E(2.80b)/V(2.80b) * Re(8.67%) + (debt cost/tax rate unavailable))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.77%
[DCF] Terminal Value 67.71% ; FCFF base≈220.9m ; Y1≈145.0m ; Y5≈66.3m
[DCF] Fair Price = 15.42 (EV 1.18b - Net Debt -706.4m = Equity 1.88b / Shares 122.1m; r=8.66% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 57.06 | EPS CAGR: 58.81% | SUE: 4.0 | # QB: 2
Revenue Correlation: 93.69 | Revenue CAGR: 40.11% | SUE: 2.10 | # QB: 6
EPS next Quarter (2026-06-30): EPS=0.68 | Chg7d=+0.043 | Chg30d=+0.043 | Revisions Net=+2 | Analysts=4
EPS current Year (2026-12-31): EPS=2.85 | Chg7d=+0.256 | Chg30d=+0.256 | Revisions Net=+4 | Growth EPS=+4.8% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=3.12 | Chg7d=+0.486 | Chg30d=+0.486 | Revisions Net=+2 | Growth EPS=+9.2% | Growth Revenue=+10.5%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.3% (Discount Rate 8.7% - Earnings Yield 7.4%)
[Growth] Growth Spread = +2.4% (Analyst 3.6% - Implied 1.3%)
P/E Forward = 9.3809
P/S = 4.7559
P/B = 2.9166
Revenue TTM = 589.0m USD
EBIT TTM = 275.6m USD
EBITDA TTM = 313.1m USD
Long Term Debt = 2.79m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 437k USD (from shortTermDebt, last quarter)
Debt = 2.79m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -706.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.09b USD (2.80b + Debt 2.79m - CCE 709.2m)
Interest Coverage Ratio = -34.80 (Ebit TTM 275.6m / Interest Expense TTM -7.92m)
EV/FCF = 10.04x (Enterprise Value 2.09b / FCF TTM 208.6m)
FCF Yield = 9.96% (FCF TTM 208.6m / Enterprise Value 2.09b)
FCF Margin = 35.42% (FCF TTM 208.6m / Revenue TTM 589.0m)
Net Margin = 36.39% (Net Income TTM 214.3m / Revenue TTM 589.0m)
Gross Margin = 85.19% ((Revenue TTM 589.0m - Cost of Revenue TTM 87.3m) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 82.94%)
Tobins Q-Ratio = 1.89 (Enterprise Value 2.09b / Total Assets 1.11b)
Interest Expense / Debt = 61.14% (Interest Expense 1.70m / Debt 2.79m)
Taxrate = 26.71% (19.2m / 71.9m)
NOPAT = 202.0m (EBIT 275.6m * (1 - 26.71%))
Current Ratio = 6.08 (Total Current Assets 894.0m / Total Current Liabilities 147.2m)
Debt / Equity = 0.00 (Debt 2.79m / totalStockholderEquity, last quarter 954.3m)
Debt / EBITDA = -2.26 (Net Debt -706.4m / EBITDA 313.1m)
Debt / FCF = -3.39 (Net Debt -706.4m / FCF TTM 208.6m)
Total Stockholder Equity = 881.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.89% (Net Income 214.3m / Total Assets 1.11b)
RoE = 24.32% (Net Income TTM 214.3m / Total Stockholder Equity 881.2m)
RoCE = 31.18% (EBIT 275.6m / Capital Employed (Equity 881.2m + L.T.Debt 2.79m))
RoIC = 22.92% (NOPAT 202.0m / Invested Capital 881.2m)
WACC = 8.66% (E(2.80b)/V(2.80b) * Re(8.67%) + (debt cost/tax rate unavailable))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.77%
[DCF] Terminal Value 67.71% ; FCFF base≈220.9m ; Y1≈145.0m ; Y5≈66.3m
[DCF] Fair Price = 15.42 (EV 1.18b - Net Debt -706.4m = Equity 1.88b / Shares 122.1m; r=8.66% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 57.06 | EPS CAGR: 58.81% | SUE: 4.0 | # QB: 2
Revenue Correlation: 93.69 | Revenue CAGR: 40.11% | SUE: 2.10 | # QB: 6
EPS next Quarter (2026-06-30): EPS=0.68 | Chg7d=+0.043 | Chg30d=+0.043 | Revisions Net=+2 | Analysts=4
EPS current Year (2026-12-31): EPS=2.85 | Chg7d=+0.256 | Chg30d=+0.256 | Revisions Net=+4 | Growth EPS=+4.8% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=3.12 | Chg7d=+0.486 | Chg30d=+0.486 | Revisions Net=+2 | Growth EPS=+9.2% | Growth Revenue=+10.5%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.3% (Discount Rate 8.7% - Earnings Yield 7.4%)
[Growth] Growth Spread = +2.4% (Analyst 3.6% - Implied 1.3%)